Commentary|Podcasts|October 9, 2026

AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?

Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.

Can artificial intelligence (AI) help turn what many believe is clinical development’s biggest variable — and most prevailing bottleneck — into a more predictable process? In this episode of the Applied Clinical Trials podcast, Matt Walz, CEO of Trialbee, a patient recruitment company, joins Mike Christel, group managing editor, MJH Life Sciences, to discuss how AI is enhancing medical screening, clinical workflows, and enrollment planning.

The conversation opens with Walz placing FDA's recent call for feedback on its AI pilot program in early-stage research within a broader federal push to win back Phase I studies from China, where faster, cheaper processes and incentives for physicians to identify research candidates have given it an edge. He argues that industry's requests for clarity around use cases, metrics, and governance reflect a key distinction: AI applied to internal workflows, where a human can stay in the loop, is very different from AI-driven decision-making based on real-world data, where bias remains a concern.

Walz also shares how Trialbee is deploying AI on both the patient-facing and operational sides of its business, explains how conversational tools are helping teams move from dashboards to more specific answers, and discusses why he believes making enrollment predictable could be a game changer for drug development timelines and costs.

Click below to listen to the audio version and subscribe to the Applied Clinical Trials Podcast:


Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
© putilov_denis - © putilov_denis - stock.adobe.com
Sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials, even though increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist.